Chromocell issues letter to stockholders from chief executive officer

Freehold, n.j., april 09, 2024 (globe newswire) -- chromocell therapeutics corporation (“chromocell”, or the “company”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its chief executive officer, frank knuettel, has issued the following letter to stockholders:
CHRO Ratings Summary
CHRO Quant Ranking